🎉 M&A multiples are live!
Check it out!

KalVista Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for KalVista Pharma and similar public comparables like Pharming, Galapagos, and Benevolent AI.

KalVista Pharma Overview

About KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.


Founded

2004

HQ

United States of America
Employees

150

Website

kalvista.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$347M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

KalVista Pharma Financials

KalVista Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, KalVista Pharma achieved revenue of n/a and an EBITDA of -$131M.

KalVista Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See KalVista Pharma valuation multiples based on analyst estimates

KalVista Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$110M -$131M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$82.3M -$92.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

KalVista Pharma Stock Performance

As of April 15, 2025, KalVista Pharma's stock price is $12.

KalVista Pharma has current market cap of $594M, and EV of $347M.

See KalVista Pharma trading valuation data

KalVista Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$347M $594M XXX XXX XXX XXX $-3.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

KalVista Pharma Valuation Multiples

As of April 15, 2025, KalVista Pharma has market cap of $594M and EV of $347M.

KalVista Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate KalVista Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for KalVista Pharma and 10K+ public comps

KalVista Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $347M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.1x XXX XXX XXX
P/E -3.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get KalVista Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

KalVista Pharma Valuation Multiples

KalVista Pharma's NTM/LTM revenue growth is Infinity%

KalVista Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, KalVista Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate KalVista Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for KalVista Pharma and other 10K+ public comps

KalVista Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

KalVista Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

KalVista Pharma M&A and Investment Activity

KalVista Pharma acquired  XXX companies to date.

Last acquisition by KalVista Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . KalVista Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by KalVista Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About KalVista Pharma

When was KalVista Pharma founded? KalVista Pharma was founded in 2004.
Where is KalVista Pharma headquartered? KalVista Pharma is headquartered in United States of America.
How many employees does KalVista Pharma have? As of today, KalVista Pharma has 150 employees.
Who is the CEO of KalVista Pharma? KalVista Pharma's CEO is Mr. Benjamin L. Palleiko.
Is KalVista Pharma publicy listed? Yes, KalVista Pharma is a public company listed on NAS.
What is the stock symbol of KalVista Pharma? KalVista Pharma trades under KALV ticker.
When did KalVista Pharma go public? KalVista Pharma went public in 2015.
Who are competitors of KalVista Pharma? Similar companies to KalVista Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of KalVista Pharma? KalVista Pharma's current market cap is $594M
Is KalVista Pharma profitable? Yes, KalVista Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.